Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals (NASDAQ:DERM)

Journey Medical (DERM) Q1 2026 earnings call: Emrosi growth, PBM/GPO access gains, and path to positive EBITDA.